Zhang D Z, Niu J Q
The First Hospital of Jilin University, Changchun 130021, China.
Zhonghua Gan Zang Bing Za Zhi. 2019 Nov 20;27(11):834-837. doi: 10.3760/cma.j.issn.1007-3418.2019.11.005.
Hepatocellular carcinoma (HCC) has a high incidence and mortality rate in China, and is the worst-than-expected cancer management disease in all provinces of the country. In recent years, systemic drug therapy for HCC has developed rapidly, especially molecular targeted drugs and immune checkpoint blocker being the most prominent. Molecular targeted drugs and immune checkpoint blocker have achieved some progress in the treatment of advanced HCC, but they still have many problems and challenges. This paper briefly introduces the latest advances of drug therapy for advanced HCC.
肝细胞癌（HCC）在中国具有较高的发病率和死亡率，是全国所有省份中癌症管理情况比预期更糟的疾病。近年来，HCC的全身药物治疗发展迅速，尤其是分子靶向药物和免疫检查点阻断剂最为突出。分子靶向药物和免疫检查点阻断剂在晚期HCC的治疗中取得了一些进展，但仍存在许多问题和挑战。本文简要介绍晚期HCC药物治疗的最新进展。
